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INTRODUCTION
Heart failure (HF) affects approximately 5.7 million Americans (1) , and the risk for developing HF increases with age (2). Prognosis for patients with HF remains relatively poor, with the 5-year survival rate estimated to be approximately 50% (3) . In addition, HF is associated with a substantial economic burden, mainly because patients require frequent hospitalization, especially those with severe HF not controlled by standard medication (4) . In 2010, direct medical costs associated with HF in the United States (US) were estimated to be approximately $21 billion, 80% of which was directly attributable to hospitalizations (1, 5) .
Relatively high resting heart rate is an indication of inadequate HF control, and is an independent predictor of cardiovascular (CV)-related morbidity (hospitalizations) and mortality in patients with left ventricular systolic dysfunction and chronic symptomatic HF (6) (7) (8) (9) (10) . In April, 2015, the US Food and Drug Administration approved ivabradine to reduce the risk of hospitalization for worsening of HF in patients with stable, symptomatic, chronic HF with left ventricular ejection fraction (LVEF) ≤ 35%, who are in sinus rhythm with a resting heart rate ≥ 70 beats per minute (bpm), and either are receiving maximally tolerated doses of or have a contraindication to beta-blockers. Because of the economic burden of HF, the objective of this study was to estimate the budget impact of introducing ivabradine into the formulary from a US payer perspective.
METHODS

Model Overview
A Microsoft Excel-based budget impact model (Figure 1 ) was developed to compare a reference scenario, which included the current standard-of-care (SoC), with a new drug scenario in which ivabradine was added to current SoC. The analysis was based on a hypothetical 1-million member US plan with a commercial (age 19 -64 years) or Medicare Advantage (generally ≥ 65 years) population. Analytically, the model used the frequency and cost of hospitalizations of US patients with HF and applied an ivabradine-driven hospitalization reduction factor derived from the Systolic Heart Failure Treatment with the I(f)Inhibitor Ivabradine Trial (SHIFT) (8) . The reduction in hospitalization costs and drug costs in the reference and new drug scenarios were then compared to assess the overall budget impact of ivabradine, expressed as incremental cost per member per month (PMPM). The model aimed to evaluate to what extent the cost of adding ivabradine to SoC was off-set by reductions in the cost of hospitalizations.
Two versions of the model were developed: 1) a Core Model calculated the budget impact of adding ivabradine to SoC by considering only the effect of ivabradine on costs associated with hospitalization for worsening HF and the cost of ivabradine; and 2) an Expanded Model included all of the elements of the Core Model as well as the impact of ivabradine on all-cause hospitalization and the costs of treating adverse events (AE) related to ivabradine treatment.
Both version of the model included the natural death rate of patients in this population based on the SHIFT SoC arm, supplemented with data from 2010 US life tables (11) and an analysis of mortality rates in patients with HF (12) . The core and the expanded model were designed to estimate budget impact up to 5 years in future. For the purpose of simplicity and balance, the manuscript reports the results for year 1 and year 3.
Model Inputs and Assumptions
Ivabradine utilization expectation
Based on projected drug utilization rates, the model used a utilization rate of 2% in Year 1 within the eligible patient population, with a 2% absolute increase for each subsequent year.
The model generated separate results for the commercial and Medicare Advantage populations.
A retrospective database analysis was conducted using the OPTUM™ research database (Optum, Inc., Eden Prairie, MN) to estimate demographics, annual cumulative hospitalization rates, and hospitalization costs for the two populations. In the commercial population, the mean age was 63 years and 43% were female; in the Medicare Advantage population, the mean age was 77 years and 54% were female.
The target eligible patient population for ivabradine was estimated from the literature and was defined as adults (≥ 18 years of age) with systolic chronic HF in New York Heart Association (NYHA) Class II, III, or IV, and normal sinus rhythm with a heart rate of ≥ 70 bpm. The target population sizes were calculated as the sum of prevalent and incident cases in the US commercial and Medicare populations estimated using multiple inputs (5, (13) (14) (15) , such as NYHA Class and heart rate ( Table 1) . The epidemiological makeup of the target population was assumed to remain constant across the model time horizon, consistent with American Heart Association methodology (5) .
Clinical Inputs
Ivabradine efficacy was derived using data from SHIFT, in which 6,505 patients with moderateto-severe (NYHA Class II, III, or IV) HF in normal sinus rhythm, with LVEF ≤ 35% and heart rate ≥ 70 bpm, and with a HF-related hospitalization within the past year, were randomized to ivabradine or placebo in addition to maximally tolerated beta-blockers and other guidelinesuggested drug therapies (8) . The model had ability to utilized annualized hospitalization rates either from clinical trial data (SHIFT) or real world US claims (OPTUM claims). The results obtained using real world US hospitalization rates are reported in this manuscript. The mortality inputs used in this model reflect natural death rates( Table 2 ). To align with ivabradine's US label, mortality benefit due to use of Ivabradine was not considered in this model.
To derive clinical inputs for patients treated with ivabradine in the new drug scenario, hospitalization rates from the reference case were adjusted based on treatment effect data derived from a post hoc analysis of the SHIFT trial population (incident rate ratio [IRR]= 0.75 over the duration of the entire trial [median = 22.9 months]) (10). For the Expanded Model which included all-cause hospitalization, annualized incidence rates for each type of hospitalization were calculated using the intent-to-treat set as the total number of events divided by the total number of patient-years at risk (from randomization until death or the end of study, whichever came first). The model calculated mutually exclusive hospitalization rates and costs for HFrelated, non-HF CV related, and non-CV related hospitalizations to avoid double-counting of events that could occur if the overlapping categories of "all-cause" and "CV-related" were used.
Mortality benefit due to adding ivabradine to SoC was not included in either model.
Cost Inputs
Because ivabradine is intended to be used as an add-on therapy and not expected to impact use of SoC, the costs of SoC drugs were excluded from the model. Hospitalization cost inputs were calculated from OPTUM research database for both populations. InGauge data that included commercial fee ranges and geographic adjustment factors were used for adverse event-related costs (16) ( Table 3 ). The hospitalization costs were estimated separately for the commercial and Medicare Advantage populations. All hospitalization cost inputs were based on insurer-paid claims (13,17) and did not include patient out-of-pocket costs or adjustment for coordination of benefits among more than one insurer. Therefore, the cost of hospitalization used in this model may not reflect the total cost. The cost for ivabradine was $4,500 per year for every patient included in the model, the wholesale acquisition cost as of April 15, 2015. Budget Impact of Ivabradine 9 The Expanded Model included a wider scope of the additional inputs related to the cost of allcause hospitalization and AEs. Costs associated with non-HF CV-and non-CV-related hospitalizations were estimated from the OPTUM research database. Using the SHIFT safety dataset, rates of AEs for both the reference and new drug scenarios were calculated as the total number of AEs divided by the number of patient-years at risk. AEs included in the model were asymptomatic bradycardia, symptomatic bradycardia, atrial fibrillation, phosphenes, and blurred vision. These AEs were selected because in SHIFT, they were among the most-frequent AEs overall and the incidence differed between the ivabradine and placebo arms; in addition, they are potentially related to ivabradine's mechanism of action (8) . Costs of AE management included cost of outpatient physician visits or emergency department visits for cardiac events of moderate or high severity and cost of comprehensive ophthalmological services for ophthalmic events (17).
Sensitivity Analyses
Multiple one-way sensitivity analyses were conducted to understand the impact of varying core model inputs and assumptions on the results ( Table 5 ). In accordance with the International Society for Pharmacoeconomics and Outcomes Research guidance on budget impact analyses (18) , alternative scenarios of potential interest to payers were tested using the Expanded Model, which considered the budget impact of all-cause hospitalizations and AEs in addition to HFrelated hospitalizations.
RESULTS
Core Model Results
In a hypothetical 1 million member plan, 1,913 commercially insured prevalent patients and 191 incident patients (total n= 2104)were eligible to receive ivabradine. Based on 2% utilization for year 1, a total of 38 patients will utilize Ivabradine and this will increase to 115 patients in year 3.
In the US commercial plan population, ivabradine costs at Year 3 were estimated to be (Table 4) .
Sensitivity Analyses
Results from one-way sensitivity analyses performed on the Core Model with commercial and Medicare Advantage populations are summarized in Table 5 . The use of alternative hospitalization rates from the SHIFT study resulted in an incremental cost increase of $0.02 PMPM and $0.59 PMPM for the commercial and Medicare Advantage populations, respectively. These changes were driven by lower overall rates of hospitalization in the SHIFT study relative to US claims data, resulting in smaller cost offsets from prevented hospitalizations ( Table 5) . Together, these findings demonstrate a consistently favorable budget impact in both populations. These data are useful because chronic HF is associated with a relatively high economic burden, and SHIFT demonstrated that for patients with chronic HF with moderate-to-severe systolic dysfunction, targeted reduction in heart rate with ivabradine treatment in combination with SoC resulted in significant reductions in hospitalization rates (8) .
The patient populations targeted in these models were as close as possible to those covered by the approved US indication for ivabradine, including patients both with and without a previous HF-related hospital admission. This is in contrast to the SHIFT study population, which included admission within the year prior to study enrollment and LVEF ≤ 35% as inclusion criteria (8) .
While the model assumes similar benefits of adding ivabradine treatment in the broader population, a clear benefit of ivabradine in reducing the risk of HF-related hospitalization in patients without a previous admission has not been rigorously established in clinical trials.
Sensitivity analyses showed that for the commercially-insured population, the biggest drivers of budget impact were hospitalization rates and ivabradine utilization. Together, these results suggest that the economic benefit of adding ivabradine to SoC will be substantially influenced by access to treatment, particularly in patient populations at progressively higher risk for HFrelated admissions. This is the first study to assess the budget impact of introducing ivabradine into the US. A separate budget impact analysis by the National Institute for Health and Care Excellence (NICE) in the United Kingdom estimated the total budget impact as approximately £4,400 per 100,000 individuals (19). This moderate budget impact together with a favorable assessment of the clinical efficacy resulted in a positive recommendation for ivabradine by NICE in the UK.
The strength of the current analysis is that it used data from real-world US medical commercial claims to derive hospitalization rates and costs in both the commercial and Medicare Advantage populations, thus making the results highly relevant to the target US populations. Similarly, the natural death rates of non-CV mortality were adjusted using data from US life tables to ensure that mortality rates were as relevant to the target population as possible.
Budget Impact of Ivabradine 13 It is important to note that the cost of SoC was not included in the model, resulting in underestimation of total treatment costs. However, because ivabradine is intended to be used in addition to SoC, exclusion of these costs does not affect incremental budget impact. Due to data limitations, costs of AE management in the Expanded Model considered only those costs associated with outpatient and emergency room visits, and did not include costs of AE associated tests, procedures, or medications; this may have led to an underestimate of the total costs associated with AE management. In addition, although the analysis suggested that incremental budget impact was relatively insensitive to AE cost, some costs related to AE management may be associated with inpatient visits (e.g., for symptomatic atrial fibrillation).
Although these costs would be captured as a component of all-cause hospitalization, they would not be specifically attributed to AE management.
In conclusion, inclusion of ivabradine in the formularies of US commercial and Medicare
Advantage plans in the US is estimated to result in a reduction of HF-related hospitalizations that offset the cost of providing ivabradine to patients. From a US payer perspective, the favorable budget impacts associated with ivabradine treatment indicate that ivabradine will be an affordable treatment option in both populations. 
